$49.58
1.49% day before yesterday
Nasdaq, Dec 24, 07:00 pm CET

Collegium Pharmaceutical, Inc. Stock price

$49.58
+4.01 8.79% 1M
+19.47 64.66% 6M
+20.93 73.05% YTD
+20.52 70.61% 1Y
+26.62 115.94% 3Y
+31.03 167.28% 5Y
+24.57 98.24% 10Y
+37.29 303.42% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.73 1.49%

Key metrics

Basic
Market capitalization
$1.6b
Enterprise Value
$2.1b
Net debt
$522.3m
Cash
$285.9m
Shares outstanding
31.6m
Valuation (TTM | estimate)
P/E
33.5 | 6.5
P/S
2.1 | 2.0
EV/Sales
2.8 | 2.6
EV/FCF
7.2
P/B
5.7
Financial Health
Equity Ratio
13.8%
Return on Equity
30.2%
ROCE
13.6%
ROIC
8.8%
Debt/Equity
2.9
Financials (TTM | estimate)
Revenue
$757.1m | $797.8m
EBITDA
$383.2m | $459.7m
EBIT
$157.0m | $311.5m
Net Income
$58.4m | $242.9m
Free Cash Flow
$289.3m
Growth (TTM | estimate)
Revenue
26.3% | 26.4%
EBITDA
12.1% | 35.6%
EBIT
-18.9% | 83.3%
Net Income
-34.0% | 251.1%
Free Cash Flow
50.3%
Margin (TTM | estimate)
Gross
57.2%
EBITDA
50.6% | 57.6%
EBIT
20.7%
Net
7.7% | 30.5%
Free Cash Flow
38.2%
More
EPS
$1.5
FCF per Share
$9.2
Short interest
22.3%
Employees
357
Rev per Employee
$1.8m
Show more

Is Collegium Pharmaceutical, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Collegium Pharmaceutical, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Collegium Pharmaceutical, Inc. forecast:

9x Buy
82%
2x Hold
18%

Analyst Opinions

11 Analysts have issued a Collegium Pharmaceutical, Inc. forecast:

Buy
82%
Hold
18%

Financial data from Collegium Pharmaceutical, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
757 757
26% 26%
100%
- Direct Costs 324 324
44% 44%
43%
433 433
16% 16%
57%
- Selling and Administrative Expenses 280 280
56% 56%
37%
- Research and Development Expense - -
-
-
383 383
12% 12%
51%
- Depreciation and Amortization 226 226
53% 53%
30%
EBIT (Operating Income) EBIT 157 157
19% 19%
21%
Net Profit 58 58
34% 34%
8%

In millions USD.

Don't miss a Thing! We will send you all news about Collegium Pharmaceutical, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Collegium Pharmaceutical, Inc. Stock News

Neutral
GlobeNewsWire
about one month ago
STOUGHTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: Jefferies London Healthcare Conference Presentation Date and Time: Wednesday, November 19, 2025, at 8:00 a.m.
Positive
Seeking Alpha
about 2 months ago
Collegium Pharmaceutical, Inc. just delivered standout Q3 results, with EPS and revenue significantly surpassing expectations, driving a 15% stock surge. COLL focuses on pain management treatments and expanded into ADHD with the recent Jornay PM acquisition, strengthening its product portfolio. Despite insider selling and a notable short interest, COLL maintains a strong cash position and manag...
Neutral
Seeking Alpha
about 2 months ago
Collegium Pharmaceutical, Inc. ( COLL ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Ian Karp Vikram Karnani - CEO, President, Executive VP & Director Scott Dreyer - Executive VP & Chief Commercial Officer Colleen Tupper - Executive VP & CFO Conference Call Participants Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Jeevan Larson - Truist Securities, In...
More Collegium Pharmaceutical, Inc. News

Company Profile

Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta IR is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Stoughton, MA.

Head office United States
CEO Vikram Karnani
Employees 357
Founded 2002
Website www.collegiumpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today